Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
Chronic kidney disease (CKD) has become a major worldwide healthcare problem, affecting an estimated 5%-10% of the world's population (Hamer and El Nahas 2006). Progression to end stage renal disease (ERSD), the need for renal replacement therapy, and the high annual death rate of dialysis patients are the most noticeable outcomes of CKD. Most patients with CKD in fact die mainly from cardiovascular disease, rather than from ERSD.
286 人阅读发布时间:2021-03-29 08:56